Lubor Gaal, Head at BMS Europe to speak at CNS Partnering meeting Sept 13-14, San Francisco
Lubor Gaal, Head of Strategic Transactions Group, Europe, at Bristol-Myers Squibb, will give a featured presentation at the 5th CNS Partnering and Deal-making Conference (Sept 13-14, 2012 in San Francisco, CA).
- (1888PressRelease) July 27, 2012 - Lubor Gaal, Head of Strategic Transactions Group, Europe, at Bristol-Myers Squibb, will give a featured talk at the 5th CNS Partnering and Deal-making Conference to be held in San Francisco, CA on September 13-14, 2012.
Dr. Gaal is responsible for Global Transactions in Neurosciences at BMS. He is BMS' point person for pharmaceutical or biotechnology companies in Europe. Prior to joining Bristol-Myers Squibb, Dr. Gaal was Head of Business Development for Neuro3d, France and CBO of Vectron Therapeutics AG, Germany. In the US, Dr. Gaal worked for Berlex Laboratories (NJ) where he was responsible for Global Cardiovascular and CNS Licensing of Schering AG. Before joining Berlex, he worked for Burrill and Company in San Francisco, where he advised biotechnology and pharmaceutical companies on business development strategies and execution. Dr. Gaal has extensive experience in evaluating and negotiating transactions with small and large companies, having worked in California, New Jersey and in Europe in the last two decades.
The 5th CNS Partnering and Deal-making is a CNS Diseases partnering and business development conference that gives global biotechnology and pharmaceutical companies an opportunity to network with high-level executives from top pharma and various biotech/pharmaceutical companies, as well as explore potential collaborations, and learn about relevant CNS Disease issues and partnerships that will affect the industry. This event also provides a unique venue for attendees to learn about CNS Diseases business development trends, the CNS disease market, and novel technologies that shape up the industry.
The conference is part of the CNS Diseases World Summit, which consists of 4 parallel tracks:
1) 6th Neurodegenerative Conditions Research and Development
2) 5th CNS Partnering and Deal-making
3) 2nd Neuropsychiatric Research and Development
4) Pain Research and Therapeutics
For more information, please visit www.gtcbio.com
###
space
space
Satisfied Users & 
Approved Press Releases
Print
Email
Report Spam